Segment Information - Schedule of Segment Loss (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||||
| Segment Reporting [Line Items] | ||||||||
| Impairment of property and equipment | $ 0 | $ 1,625,000 | $ 0 | |||||
| Total operating expenses | $ 24,384,000 | 17,061,000 | 38,859,000 | 34,402,000 | ||||
| Loss from operations | (24,384,000) | (17,061,000) | (38,859,000) | (34,402,000) | ||||
| Interest and other income, net | 691,000 | 1,386,000 | 1,611,000 | 2,969,000 | ||||
| Net loss | (23,693,000) | (15,675,000) | (37,248,000) | (31,433,000) | ||||
| Operating Segments | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Facilities related | 6,720,000 | 2,400,000 | 9,243,000 | 4,699,000 | ||||
| Stock-based compensation and depreciation | 4,480,000 | 2,010,000 | 6,134,000 | 4,124,000 | ||||
| Impairment of property and equipment | 1,625,000 | 0 | 1,625,000 | 0 | ||||
| Total operating expenses | 24,384,000 | 17,061,000 | 38,859,000 | 34,402,000 | ||||
| Loss from operations | (24,384,000) | (17,061,000) | (38,859,000) | (34,402,000) | ||||
| Interest and other income, net | 691,000 | 1,386,000 | 1,611,000 | 2,969,000 | ||||
| Net loss | (23,693,000) | (15,675,000) | (37,248,000) | (31,433,000) | ||||
| Operating Segments | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Compensation and benefits (excludes stock-based compensation) | 1,893,000 | 1,528,000 | 3,276,000 | 3,102,000 | ||||
| Other costs | [1] | 542,000 | 618,000 | 1,003,000 | 1,344,000 | |||
| Professional service fees | 2,266,000 | 810,000 | 3,047,000 | 1,807,000 | ||||
| Insurance | 136,000 | 202,000 | 335,000 | 420,000 | ||||
| Operating Segments | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Compensation and benefits (excludes stock-based compensation) | 2,495,000 | 3,217,000 | 4,625,000 | 6,512,000 | ||||
| Clinical trial costs | 1,331,000 | 2,448,000 | 3,943,000 | 5,298,000 | ||||
| Outsourced services & Consulting | 2,200,000 | 3,132,000 | 4,409,000 | 5,514,000 | ||||
| Lab and pharmacology supplies | 67,000 | 256,000 | 210,000 | 546,000 | ||||
| Other costs | [2] | $ 629,000 | $ 440,000 | $ 1,009,000 | $ 1,036,000 | |||
| ||||||||
| X | ||||||||||
- Definition Clinical trial costs No definition available.
|
| X | ||||||||||
- Definition Compensation and benefits expenses No definition available.
|
| X | ||||||||||
- Definition Facilities related expense. No definition available.
|
| X | ||||||||||
- Definition Lab and pharmacology supplies. No definition available.
|
| X | ||||||||||
- Definition Outsourced services and consulting. No definition available.
|
| X | ||||||||||
- Definition Stock-based compensation and depreciation. No definition available.
|
| X | ||||||||||
- Definition The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of impairment loss for long-lived asset held and used. Includes, but is not limited to, impairment loss for long-lived asset to be disposed of other than by sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|